<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02243059</url>
  </required_header>
  <id_info>
    <org_study_id>142030</org_study_id>
    <nct_id>NCT02243059</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer</brief_title>
  <acronym>MILO</acronym>
  <official_title>Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Advanced epithelial ovarian cancer has high morbidity and mortality. Patients presenting with
      advanced stage ovarian cancer often have cancer spread to regional lymph nodes. Imaging
      strategies to depict involved lymph nodes are currently not successful. The purpose of this
      study is to evaluate if magnetic resonance imaging (MRI) with gadofosveset trisodium contrast
      enhancement (GDF-MRI) and diffusion weighted imaging (DW-MRI) is able to identify involved
      lymph nodes in a preoperative setting. This could guide the surgeon during surgery to dissect
      lymph nodes which could lead to an optimal diagnosis/staging with the lowest possible
      morbidity. We want to determine the optimal imaging settings and feasibility of MRI for the
      detection of pathological lymph nodes in women with advanced (FIGO stage IIB-IV) ovarian
      cancer undergoing primary debulking surgery and compare this to conventional imaging with
      computer tomography (CT).
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Problems with availability of study medicine in clinical center
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of MRI in depicting lymph nodes.</measure>
    <time_frame>One year</time_frame>
    <description>Primary outcome measure is to determine the optimal imaging settings and feasibility of MRI combined with DW-MRI and GDF-MRI (gadofosveset-MRI) in the identification of pathologic lymph nodes in women with advanced stage epithelial ovarian cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy of MRI.</measure>
    <time_frame>One year</time_frame>
    <description>Sensitivity, specificity, positive predictive value and negative predictive value for the detection of metastatic lymph nodes will be calculated for MRI (+/- DW-MRI and GDF-MRI) and compared with conventional CT imaging.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>GDF-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this pilot study, all included patients will undergo conventional MRI with contrast enhancement (gadofosveset trisodium) and diffusion weighted MRI.
Ablavar™ solution contains 244 mg/mL (0.25 mmol/mL) gadofosveset trisodium. 0.03 mmol/kg of gadofosveset will be administered by manual injection as a single intravenous bolus injection over a period of time up to 30 seconds followed by a 25-30 ml saline flush. In practice, this comes down to the maximum of one vial for one patient (one vial contains 10 ml solution, which contains a total of 2.50 mmol of gadofosveset trisodium equivalent to 2.27 g of gadofosveset).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadofosveset trisodium (Ablavar™ )</intervention_name>
    <arm_group_label>GDF-MRI</arm_group_label>
    <other_name>Ablavar</other_name>
    <other_name>MS-325</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MRI</intervention_name>
    <arm_group_label>GDF-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-pregnant female

          -  Expected FIGO stage IIB-IV epithelial ovarian carcinoma

          -  Scheduled for primary debulking surgery

          -  Written informed consent

          -  At least 18 years of age.

        Exclusion Criteria:

          -  Patients estimated to have more benefit from neoadjuvant chemotherapy

          -  Ineligibility to undergo MRI

               -  Non-MR compatible metallic implants or foreign bodies (ferromagnetic aneurysm
                  clip, pacemaker, neurostimulation system, etcetera).

               -  Claustrophobia

          -  Ineligibility to receive gadofosveset contrast (history of contrast allergy,

               -  History of a prior allergic reaction to the active substance or to any of the
                  excipients of Ablavar™.

               -  Impaired kidney function (Glomerular Filtration Rate &lt;30 ml/min/1.73m2).

          -  Previous para-aortic or pelvic lymphadenectomy

          -  History of a malignant tumour.

          -  Pregnant or lactating patients. Incapacitated subjects
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toon Van Gorp, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Maastricht / GROW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Pereira A, Magrina JF, Rey V, Cortes M, Magtibay PM. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol. 2007 Jun;105(3):604-8. Epub 2007 Feb 23.</citation>
    <PMID>17321572</PMID>
  </reference>
  <reference>
    <citation>Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P, Pomel C, Lhommé C, Duvillard P, Castaigne D. Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003 Aug;197(2):198-205.</citation>
    <PMID>12892797</PMID>
  </reference>
  <reference>
    <citation>Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80.</citation>
    <PMID>8166218</PMID>
  </reference>
  <reference>
    <citation>Kim HS, Ju W, Jee BC, Kim YB, Park NH, Song YS, Kim SC, Kang SB, Kim JW. Systematic lymphadenectomy for survival in epithelial ovarian cancer: a meta-analysis. Int J Gynecol Cancer. 2010 May;20(4):520-8. doi: 10.1111/IGC.0b013e3181d6de1d.</citation>
    <PMID>20686371</PMID>
  </reference>
  <reference>
    <citation>Maggioni A, Benedetti Panici P, Dell'Anna T, Landoni F, Lissoni A, Pellegrino A, Rossi RS, Chiari S, Campagnutta E, Greggi S, Angioli R, Manci N, Calcagno M, Scambia G, Fossati R, Floriani I, Torri V, Grassi R, Mangioni C. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006 Sep 18;95(6):699-704. Epub 2006 Aug 29.</citation>
    <PMID>16940979</PMID>
  </reference>
  <reference>
    <citation>Onda T, Yoshikawa H, Yokota H, Yasugi T, Taketani Y. Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy. Cancer. 1996 Aug 15;78(4):803-8.</citation>
    <PMID>8756375</PMID>
  </reference>
  <reference>
    <citation>Kumar Dhingra V, Kand P, Basu S. Impact of FDG-PET and -PET/CT imaging in the clinical decision-making of ovarian carcinoma: an evidence-based approach. Womens Health (Lond). 2012 Mar;8(2):191-203. doi: 10.2217/whe.11.91. Review.</citation>
    <PMID>22375721</PMID>
  </reference>
  <reference>
    <citation>Wakefield JC, Downey K, Kyriazi S, deSouza NM. New MR techniques in gynecologic cancer. AJR Am J Roentgenol. 2013 Feb;200(2):249-60. doi: 10.2214/AJR.12.8932. Review. Erratum in: AJR Am J Roentgenol. 2013 May;200(5):1174.</citation>
    <PMID>23345344</PMID>
  </reference>
  <reference>
    <citation>Lin G, Ho KC, Wang JJ, Ng KK, Wai YY, Chen YT, Chang CJ, Ng SH, Lai CH, Yen TC. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J Magn Reson Imaging. 2008 Jul;28(1):128-35. doi: 10.1002/jmri.21412.</citation>
    <PMID>18581404</PMID>
  </reference>
  <reference>
    <citation>Yamashita T, Takahara T, Kwee TC, Kawada S, Horie T, Inomoto C, Hashida K, Yamamuro H, Myojin K, Luijten PR, Imai Y. Diffusion magnetic resonance imaging with gadofosveset trisodium as a negative contrast agent for lymph node metastases assessment. Jpn J Radiol. 2011 Jan;29(1):25-32. doi: 10.1007/s11604-010-0513-2. Epub 2011 Jan 26.</citation>
    <PMID>21264658</PMID>
  </reference>
  <reference>
    <citation>Low RN, Barone RM. Combined diffusion-weighted and gadolinium-enhanced MRI can accurately predict the peritoneal cancer index preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2012 May;19(5):1394-1401. doi: 10.1245/s10434-012-2236-3.</citation>
    <PMID>22302265</PMID>
  </reference>
  <reference>
    <citation>Lambregts DM, Beets GL, Maas M, Kessels AG, Bakers FC, Cappendijk VC, Engelen SM, Lahaye MJ, de Bruïne AP, Lammering G, Leiner T, Verwoerd JL, Wildberger JE, Beets-Tan RG. Accuracy of gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer. Ann Surg. 2011 Mar;253(3):539-45. doi: 10.1097/SLA.0b013e31820b01f1.</citation>
    <PMID>21239980</PMID>
  </reference>
  <reference>
    <citation>Schipper RJ, Smidt ML, van Roozendaal LM, Castro CJ, de Vries B, Heuts EM, Keymeulen KB, Wildberger JE, Lobbes MB, Beets-Tan RG. Noninvasive nodal staging in patients with breast cancer using gadofosveset-enhanced magnetic resonance imaging: a feasibility study. Invest Radiol. 2013 Mar;48(3):134-9. doi: 10.1097/RLI.0b013e318277f056. Erratum in: Invest Radiol. 2013 May;48(5):332.</citation>
    <PMID>23262788</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>September 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2014</study_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Gadofosveset trisodium</keyword>
  <keyword>Nodal imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

